BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 121 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is 3.70 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $707,540 | +0.3% | 99,935 | -0.3% | 0.00% | – |
| Q2 2023 | $705,605 | -12.7% | 100,228 | +3.4% | 0.00% | – |
| Q1 2023 | $808,146 | -80.3% | 96,900 | -72.9% | 0.00% | -100.0% |
| Q4 2022 | $4,098,991 | -10.3% | 357,055 | -1.5% | 0.00% | 0.0% |
| Q3 2022 | $4,569,000 | +53.5% | 362,602 | +28.9% | 0.00% | 0.0% |
| Q2 2022 | $2,977,000 | -18.0% | 281,276 | +26.0% | 0.00% | 0.0% |
| Q1 2022 | $3,630,000 | +28.2% | 223,280 | +9.2% | 0.00% | 0.0% |
| Q4 2021 | $2,831,000 | -5.5% | 204,425 | -1.9% | 0.00% | 0.0% |
| Q3 2021 | $2,995,000 | -74.8% | 208,364 | -72.3% | 0.00% | -66.7% |
| Q2 2021 | $11,891,000 | -18.5% | 752,112 | -47.5% | 0.00% | -25.0% |
| Q1 2021 | $14,582,000 | +5183.3% | 1,433,838 | +3766.7% | 0.00% | – |
| Q4 2020 | $276,000 | +573.2% | 37,082 | +211.8% | 0.00% | – |
| Q3 2020 | $41,000 | -25.5% | 11,894 | +3.8% | 0.00% | – |
| Q2 2020 | $55,000 | -99.0% | 11,463 | -99.2% | 0.00% | -100.0% |
| Q2 2019 | $5,483,000 | -23.7% | 1,446,732 | +63.9% | 0.00% | -50.0% |
| Q1 2019 | $7,186,000 | -11.4% | 882,910 | -12.1% | 0.00% | -33.3% |
| Q4 2018 | $8,109,000 | +19.5% | 1,004,725 | +13.0% | 0.00% | +50.0% |
| Q3 2018 | $6,787,000 | +25.8% | 889,392 | -5.5% | 0.00% | 0.0% |
| Q2 2018 | $5,395,000 | +20.1% | 941,595 | -0.0% | 0.00% | 0.0% |
| Q1 2018 | $4,491,000 | -4.4% | 941,651 | -1.6% | 0.00% | 0.0% |
| Q4 2017 | $4,696,000 | -6.3% | 956,493 | +0.0% | 0.00% | 0.0% |
| Q3 2017 | $5,011,000 | -5.8% | 956,150 | -0.0% | 0.00% | 0.0% |
| Q2 2017 | $5,317,000 | -33.8% | 956,224 | +0.0% | 0.00% | -33.3% |
| Q1 2017 | $8,031,000 | +31.2% | 956,098 | -1.1% | 0.00% | +50.0% |
| Q4 2016 | $6,121,000 | +43.5% | 966,854 | -0.0% | 0.00% | +100.0% |
| Q3 2016 | $4,266,000 | -62.7% | 967,292 | -12.6% | 0.00% | -80.0% |
| Q4 2015 | $11,423,000 | -16.4% | 1,106,873 | -7.7% | 0.01% | -16.7% |
| Q3 2015 | $13,668,000 | +273260.0% | 1,198,914 | +331091.7% | 0.01% | – |
| Q2 2015 | $5,000 | -96.0% | 362 | -97.8% | 0.00% | – |
| Q4 2013 | $125,000 | +8.7% | 16,446 | +4.1% | 0.00% | – |
| Q3 2013 | $115,000 | +379.2% | 15,796 | 0.0% | 0.00% | – |
| Q2 2013 | $24,000 | – | 15,796 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management II, LLC | 6,071,142 | $38,430,000 | 18.43% |
| RTW INVESTMENTS, LP | 4,078,895 | $25,819,000 | 9.72% |
| VHCP Management, LLC | 1,155,104 | $7,312,000 | 7.86% |
| RA Capital Management | 2,989,795 | $18,925,000 | 2.68% |
| DLD Asset Management, LP | 1,258,700 | $7,967,000 | 2.61% |
| Avoro Capital Advisors LLC | 1,631,502 | $10,327,000 | 2.09% |
| Ghost Tree Capital, LLC | 1,150,000 | $7,280,000 | 1.75% |
| GREAT POINT PARTNERS LLC | 725,000 | $4,589,000 | 0.94% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,237,734 | $20,495,000 | 0.84% |
| Baker Brothers Advisors | 10,963,944 | $69,402,000 | 0.68% |